Microscopic Polyangiitis (MPA) (Immunology) - Drugs in Development, 2021

March 2021 | 69 pages | ID: M89803CD04A3EN
Global Markets Direct

Abstracts

Microscopic Polyangiitis (MPA) (Immunology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis (MPA) - Drugs in Development, 2021, provides an overview of the Microscopic Polyangiitis (MPA) (Immunology) pipeline landscape.

Microscopic polyangiitis is an ill-defined autoimmune disease characterized by a systemic, pauci-immune, necrotizing, small-vessel vasculitis without clinical or pathological evidence of necrotizing granulomatous inflammation. The signs and symptoms of microscopic polyangiitis may resemble those of granulomatosis with polyangiitis (GPA) (another form of small-vessel vasculitis) but lacks the significant upper respiratory tract involvement frequently seen in people affected by GPA.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Microscopic Polyangiitis (MPA) - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Microscopic Polyangiitis (MPA) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 3, 1, 1, 1 and 1 respectively.

Microscopic Polyangiitis (MPA) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA) (Immunology).
• The pipeline guide reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Microscopic Polyangiitis (MPA) (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Microscopic Polyangiitis (MPA) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA) (Immunology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Microscopic Polyangiitis (MPA) (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Microscopic Polyangiitis (MPA) - Overview
Microscopic Polyangiitis (MPA) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Microscopic Polyangiitis (MPA) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development
Biogen Inc
ChemoCentryx Inc
InflaRx NV
Mabion SA
Nanolek LLC
Pharmapraxis
Teijin Pharma Ltd
Microscopic Polyangiitis (MPA) - Drug Profiles
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vilobelimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Microscopic Polyangiitis (MPA) - Dormant Projects
Microscopic Polyangiitis (MPA) - Discontinued Products
Microscopic Polyangiitis (MPA) - Product Development Milestones
Featured News & Press Releases
Nov 03, 2020: VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
Jan 30, 2020: The CHMP recommended extensions of indication for MabThera
Sep 30, 2019: Roche’s Rituxan secures approval for first paediatric indication
Jun 12, 2019: FDA grants priority review to Genentech’s Rituxan (Rituximab) in children with two rare blood vessel disorders
Nov 15, 2018: Roche receives positive CHMP opinion to expand MabThera for the treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA
Mar 22, 2013: Roche Receives CHMP Positive Opinion For MabThera
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Microscopic Polyangiitis (MPA), 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Microscopic Polyangiitis (MPA) - Pipeline by Biogen Inc, 2021
Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx Inc, 2021
Microscopic Polyangiitis (MPA) - Pipeline by InflaRx NV, 2021
Microscopic Polyangiitis (MPA) - Pipeline by Mabion SA, 2021
Microscopic Polyangiitis (MPA) - Pipeline by Nanolek LLC, 2021
Microscopic Polyangiitis (MPA) - Pipeline by Pharmapraxis, 2021
Microscopic Polyangiitis (MPA) - Pipeline by Teijin Pharma Ltd, 2021
Microscopic Polyangiitis (MPA) - Dormant Projects, 2021
Microscopic Polyangiitis (MPA) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Microscopic Polyangiitis (MPA), 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021